Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

V. Molecular classification and risk stratification of myeloma.

Bergsagel PL, Chesi M.

Hematol Oncol. 2013 Jun;31 Suppl 1:38-41. doi: 10.1002/hon.2065. Review. No abstract available.

2.

Early genetic events provide the basis for a clinical classification of multiple myeloma.

Kuehl WM, Bergsagel PL.

Hematology Am Soc Hematol Educ Program. 2005:346-52.

PMID:
16304402
3.

Plasma cell myeloma.

Lin P.

Hematol Oncol Clin North Am. 2009 Aug;23(4):709-27. doi: 10.1016/j.hoc.2009.04.012. Review.

PMID:
19577166
4.

Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.

Sáez B, Martín-Subero JI, Lahortiga I, Largo C, Larrayoz MJ, Odero MD, Prosper F, Cigudosa JC, Siebert R, Calasanz MJ.

Cancer Genet Cytogenet. 2007 May;175(1):65-8.

PMID:
17498561
5.

Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum..

Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064.

6.

Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Schmidt-Hieber M, Gutiérrez ML, Pérez-Andrés M, Paiva B, Rasillo A, Tabernero MD, Sayagués JM, Lopez A, Bárcena P, Sanchez ML, Gutiérrez NC, San Miguel JF, Orfao A.

Haematologica. 2013 Feb;98(2):279-87. doi: 10.3324/haematol.2011.060632.

7.

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL.

Blood. 1998 Nov 1;92(9):3025-34.

8.

Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.

Martin LD, Harizanova J, Righolt CH, Zhu G, Mai S, Belch AR, Pilarski LM.

Genes Chromosomes Cancer. 2013 Jun;52(6):523-37. doi: 10.1002/gcc.22049.

PMID:
23460268
9.

Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Kuehl WM, Bergsagel PL.

J Clin Invest. 2012 Oct;122(10):3456-63. doi: 10.1172/JCI61188. Review.

10.

FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.

Quintero-Rivera F, El-Sabbagh Badr R, Rao PN.

Cancer Genet Cytogenet. 2009 Nov;195(1):92-3. doi: 10.1016/j.cancergencyto.2009.06.018. No abstract available.

PMID:
19837276
11.

Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.

Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T, Schröck E, Ried T, Kuehl WM.

Blood. 1998 Jun 15;91(12):4457-63.

12.

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2005 Feb;42(2):117-27.

PMID:
15543617
13.

The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH.

Blood. 2008 Jan 15;111(2):856-64.

14.

[Chromosomal abnormalities and clonal evolution in multiple myeloma].

Ishida T.

Rinsho Ketsueki. 2014 Oct;55(10):2036-45. Review. Japanese. No abstract available.

PMID:
25297769
15.

Molecular genetical examinations of multiple myeloma and other B-cell malignancies.

Kita K, Miwa H, Ohno T, Shirakawa S.

Nihon Ketsueki Gakkai Zasshi. 1986 Dec;49(8):1729-39. No abstract available.

PMID:
3105207
16.

A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR.

Kaiser MF, Walker BA, Hockley SL, Begum DB, Wardell CP, Gonzalez D, Ross FM, Davies FE, Morgan GJ.

Leukemia. 2013 Aug;27(8):1754-7. doi: 10.1038/leu.2013.12. No abstract available.

PMID:
23318961
17.

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.

Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R.

Haematologica. 2014 Mar;99(3):511-8. doi: 10.3324/haematol.2013.093500.

18.

Molecular pathogenesis of multiple myeloma: basic and clinical updates.

Chesi M, Bergsagel PL.

Int J Hematol. 2013 Mar;97(3):313-23. doi: 10.1007/s12185-013-1291-2. Review.

19.

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.

Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Lawrie CH.

Biol Direct. 2011 May 18;6:23. doi: 10.1186/1745-6150-6-23.

20.

A molecular study of the t(4;14) in multiple myeloma.

Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ.

Br J Haematol. 2002 Aug;118(2):514-20.

PMID:
12139740
Items per page

Supplemental Content

Support Center